This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Milford, MA-based, Waters Corp. is an analytical instrument manufacturer and offers practical and sustainable products for laboratory-dependent organizations. Moreover, Waters provides analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies. The company’s products are used by pharmaceutical, life science, biochemical, industrial, academic and government customers, working in research and development, quality assurance and other laboratory applications. The company operates in Asia, Americas and Europe. Waters organizes its business into two operating segments: Waters Division and TA Division. Waters Division (88.8% of total revenues in 2019) - High Performance and Ultra Performance Liquid Chromatography (HPLC and UPLC). TA Division (11.2% of total revenues in 2019)- Thermal Analysis, Rheometry and Calorimetry.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Waters (WAT) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WAT Earnings & Sales Surpass Estimates in Q4, Shares Rise
by Zacks Equity Research
WAT's fourth-quarter 2024 results reflect strong pharma growth and robust gains across all regions. However, forex headwinds hurt.
Waters (WAT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 1.99% and 1.82%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of 63.64% and 2.36%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View
by Zacks Equity Research
WAT's third-quarter 2024 results show growth in the pharma and industrial sectors. A dip in China sales creates headwinds.
Waters (WAT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 9.33% and 3.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tactile Systems Technology (TCMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Waters (WAT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Waters (WAT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Waters (WAT) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphering Waters (WAT) International Revenue Trends
by Zacks Equity Research
Explore how Waters' (WAT) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Waters (WAT) Q2 Earnings & Sales Beat Estimates, Fall Y/Y
by Zacks Equity Research
Waters' (WAT) second-quarter results are hurt by weak end-market momentum and softness in Asia, Americas and Europe.
Compared to Estimates, Waters (WAT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Waters (WAT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 3.14% and 1.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Sensus Healthcare (SRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Waters (WAT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) second-quarter 2024 results are likely to reflect strength in the large molecule and PFAS testing markets amid weakening demand in China.
Analysts Estimate Waters (WAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IQV vs. WAT: Which Stock Is the Better Value Option?
Agilent (A) Boosts Reach to Lab Researchers With New Devices
by Zacks Equity Research
Agilent (A) boosts its presence in the mass spectrometry market with the launch of the Agilent 7010D Triple Quadrupole GC/MS System and the Agilent ExD Cell.
Why Is Waters (WAT) Down 5.1% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.